[Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia].
CONCLUSION: Despite the potential initial severity of rituximab-induced thrombocytopenia in CLL, chemotherapy should not be discontinued; tolerance might increase as the hematologic disorder is controlled.
PMID: 27639907 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
More News: Acute Leukemia | Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Internal Medicine | Leukemia | Rituxan | Thrombocytopenia | Toxicology